How can the U.S. cultivate a healthy and competitive biosimilars market?

3:00 PM - 4:00 PM, Wednesday, June 10, 2020 ・ Room 1B
Biologics have revolutionized treatment for serious diseases and profoundly impacted millions of patients. Since enactment of the Biologics Price Competition and Innovation Act, the U.S. biosimilars market has made great progress. Currently, the FDA has approved 26 biosimilars referencing 9 different biologics with 15 on the market. 80 products are in FDA’s biosimilar program.

Extensive debate continues about biosimilar progress and what it will take to achieve a competitive U.S. healthcare market with biosimilars playing a key role, especially as anticipated savings over the next 5 to 10 years totals approximately $150 billion.

This panel will share diverse perspectives on how the U.S. can:
• Encourage competition between biosimilars and reference biologics;
• Promote accurate educational content that increases confidence in biosimilars; and
• Implement regulatory standards to demonstrate biosimilarity and interchangeability, and facilitate accurate product identification.
Speaker
photo
Executive Director, Global Value, Access and Policy, Biosimilars
Amgen